<DOC>
	<DOCNO>NCT01328093</DOCNO>
	<brief_summary>The purpose study determine whether weight gain significantly less LY2140023 aripiprazole patient schizophrenia .</brief_summary>
	<brief_title>A Comparison Study LY2140023 Aripiprazole Schizophrenia Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Clinical diagnosis schizophrenia Female patient childbearing age must test negative pregnancy screen agree use single , effective , medically acceptable method birth control Patients must require initiation modification current antipsychotic treatment outpatient Patients must consider reliable , level understanding sufficient perform test examination require protocol , willing perform study procedures Patients must able understand nature study give informed consent Have treatment aripiprazole past 2 month aripiprazole nonresponders Patients pregnant , nursing , intend become pregnant within 30 day complete study Hospitalized within 2 week screen hospitalized exacerbation symptom schizophrenia discharge date past 2 month Patients actively suicidal Patients uncorrected narrowangle glaucoma , history current seizure disorder , uncontrolled diabetes , certain disease liver , renal insufficiency , uncontrolled thyroid condition serious unstable illness Patients electroconvulsive therapy ( ECT ) within 3 month prior screen ECT time study Patients know medical history Human Immunodeficiency Virus positive ( HIV+ ) status Test positive ( 1 ) Hepatitis C virus antibody ( 2 ) Hepatitis B surface antigen ( HBsAg ) without positive Hepatitis B core total antibody Patients correct QT interval ( Bazett 's ; QTcB ) &gt; 450 msec ( male ) &gt; 470 msec ( female ) screen Patients history inadequate clinical response antipsychotic treatment schizophrenia Patients receive treatment depot formulation antipsychotic medication within 1 dose interval , minimum 4 week , prior screen Are currently enrol , discontinue within last 60 day , clinical trial involve investigational product unapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Have psychiatric diagnosis addition schizophrenia Have previously complete withdrawn study , study investigate LY2140023 predecessor molecule glutamatergic activity Patients receive adequate treatment trial , opinion investigator , clozapine dos great 200 mg daily within 12 month prior screen , receive clozapine month screen Diagnosis substanceinduced psychosis within 7 day screen ( time study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>